Nektar initiates Phase 3 atopic dermatitis trials; Q2 net loss narrows 2% to $40.6M on below-the-line factors

Filed August 14, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 8, 2025 · ~2 min read

Key Changes

• high

  Operating loss widened 17% to $42.3M while net loss narrowed 2.3% to $40.6M ($1.23/share). The net-income improvement did not come from operations; interest income rose $7.3M to $9.3M on higher cash balances following equity raises.

  MD&A: Operating Results verify on EDGAR →
• high

  Phase 3 ZENITH AD program initiated in July 2026 with two global registrational trials (AD-1, AD-2) in moderate-to-severe atopic dermatitis; third trial (AD-3) planned for treatment-experienced patients. Phase 3 alopecia areata trial (ZENITH-AA-1) planned for early 2027.

  MD&A: Clinical Programs verify on EDGAR →
• high

  R&D expense rose 24% to up to $74.8M for the six months as Phase 3 trial start-up and manufacturing scale-up began.

  Notes: Equity Financings & Balance Sheet view on EDGAR →